Department of Paediatrics, University of Malaya Medical Centre, Kuala Lumpur, Malaysia.
J Pediatr Gastroenterol Nutr. 2010 Mar;50(3):295-302. doi: 10.1097/MPG.0b013e3181bf0ef7.
Graft rejection and disease recurrence are well-recognized complications of liver transplantation (LT) for autoimmune hepatitis (AIH) and autoimmune sclerosing cholangitis (AISC). We describe indications and outcome of LT for childhood AIH and AISC.
Twenty-year retrospective review of a cohort of children (n = 101) with AIH, AISC, or AIH/sclerosing cholangitis overlap syndrome from a single center.
AIH type 1 (AIH1, n = 67) was more common than AIH type 2 (AIH2, n = 18), AISC (n = 8), or overlap syndrome (n = 8). Overall, 18 patients (18%) required LT, the indications being failure of medical therapy (n = 16) and fulminant liver failure (n = 2). Patients with AIH who required LT had a more prolonged prothrombin time at presentation compared with those who did not undergo transplantation (P = 0.01). Patients with AIH1 who received LT had a lower aspartate transaminase (P = 0.009) and alanine transaminase (P = 0.02) levels at initial diagnosis compared with those with AIH1 who did not undergo transplantation. Post-LT, 11 patients (61%) had 18 episodes of rejection, most were steroid sensitive. Disease recurrence was observed in 7 patients (39%, median duration post-LT 33 months), more common in AIH2 (80% recurrence rate), and those taking cyclosporine (71%, 5/7 patients) compared with those taking tacrolimus (18%, 2/11 patients; P < 0.05) and in 3 of 3 children who did not have maintenance steroids post-LT. The overall 5- and 7-year post-LT survival rate was 94% and 88%, respectively.
LT is a good therapeutic option for progressive AIH and AISC, although recurrence of the primary autoimmune process limits the outcome.
肝移植(LT)治疗自身免疫性肝炎(AIH)和自身免疫性硬化性胆管炎(AISC)后,移植物排斥和疾病复发是公认的并发症。我们描述了 LT 治疗儿童 AIH 和 AISC 的适应证和结果。
对来自单一中心的一组儿童(n=101)的 AIH、AISC 或 AIH/硬化性胆管炎重叠综合征进行了 20 年的回顾性分析。
AIH 1 型(AIH1,n=67)比 AIH 2 型(AIH2,n=18)、AISC(n=8)或重叠综合征(n=8)更为常见。总体而言,18 例患者(18%)需要 LT,适应证为药物治疗失败(n=16)和暴发性肝衰竭(n=2)。需要 LT 的 AIH 患者与未接受移植的患者相比,初次就诊时的凝血酶原时间延长(P=0.01)。接受 LT 的 AIH1 患者的天冬氨酸转氨酶(P=0.009)和丙氨酸转氨酶(P=0.02)初始诊断水平低于未接受移植的患者。LT 后,11 例(61%)患者发生 18 次排斥反应,大多数对类固醇敏感。7 例(39%,LT 后中位时间 33 个月)发生疾病复发,AIH2 更为常见(80%复发率),接受环孢素治疗的患者(71%,7/11 例)比接受他克莫司治疗的患者(18%,11/11 例;P<0.05)更常见,3 例未接受 LT 后维持性类固醇治疗的患者中也有 3 例复发。LT 后 5 年和 7 年的总体生存率分别为 94%和 88%。
LT 是进展性 AIH 和 AISC 的良好治疗选择,尽管原发性自身免疫过程的复发限制了其结果。